(NTR) Nutrien - Overview
Exchange: NYSE •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA67077M1086
Stock: Fertilizers, Crop Nutrients, Seeds, Crop Protection, Services
Total Rating 60
Risk 91
Buy Signal 0.15
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.86% |
| Yield on Cost 5y | 5.19% |
| Yield CAGR 5y | 4.33% |
| Payout Consistency | 100.0% |
| Payout Ratio | 54.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 29.8% |
| Relative Tail Risk | -3.38% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.14 |
| Alpha | 32.60 |
| Character TTM | |
|---|---|
| Beta | 0.351 |
| Beta Downside | 0.391 |
| Drawdowns 3y | |
|---|---|
| Max DD | 44.33% |
| CAGR/Max DD | -0.04 |
Description: NTR Nutrien December 17, 2025
Nutrien Ltd. (NYSE:NTR) is a vertically integrated crop-input provider operating through four segments: Nutrien Ag Solutions (distribution of nutrients, crop protection, seeds, and related services), Potash (granular and standard potash products), Nitrogen (ammonia, urea, and other nitrogen solutions), and Phosphate (solid and liquid fertilizers plus industrial/feed products). Headquartered in Saskatoon, Canada, the company was formed in 2017 through the merger of Agrium and PotashCorp.
Key recent metrics: FY 2023 revenue reached approximately $27.4 billion with an EBITDA margin near 15 %; net debt stood at roughly $6.5 billion, and the firm maintained a dividend yield around 3.5 %. Economic drivers include global grain production growth (which fuels fertilizer demand), volatile nitrogen pricing linked to natural gas costs, and tightening potash supply due to limited new capacity. A sector-wide catalyst is the accelerating adoption of precision-agriculture and climate-smart nitrogen technologies, which can boost premium product uptake.
For a concise, data-rich overview of Nutrien’s valuation and risk profile, the ValueRay platform provides a useful dashboard to explore further.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.20 > 1.0 |
| NWC/Revenue: 15.82% < 20% (prev 10.98%; Δ 4.83% < -1%) |
| CFO/TA 0.08 > 3% & CFO 4.14b > Net Income 1.80b |
| Net Debt (13.56b) to EBITDA (5.61b): 2.42 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (485.8m) vs 12m ago -1.84% < -2% |
| Gross Margin: 30.19% > 18% (prev 0.29%; Δ 2990 % > 0.5%) |
| Asset Turnover: 51.20% > 50% (prev 51.16%; Δ 0.04% > 0%) |
| Interest Coverage Ratio: 4.66 > 6 (EBITDA TTM 5.61b / Interest Expense TTM 691.6m) |
Altman Z'' 2.68
| A: 0.08 (Total Current Assets 14.47b - Total Current Liabilities 10.27b) / Total Assets 51.83b |
| B: 0.23 (Retained Earnings 11.84b / Total Assets 51.83b) |
| C: 0.06 (EBIT TTM 3.22b / Avg Total Assets 51.87b) |
| D: 0.94 (Book Value of Equity 25.06b / Total Liabilities 26.67b) |
| Altman-Z'' Score: 2.68 = A |
Beneish M -3.15
| DSRI: 0.99 (Receivables 7.69b/7.79b, Revenue 26.56b/26.56b) |
| GMI: 0.96 (GM 30.19% / 29.06%) |
| AQI: 0.95 (AQ_t 0.29 / AQ_t-1 0.30) |
| SGI: 1.00 (Revenue 26.56b / 26.56b) |
| TATA: -0.05 (NI 1.80b - CFO 4.14b) / TA 51.83b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of NTR shares?
As of January 30, 2026, the stock is trading at USD 71.13 with a total of 2,116,329 shares traded.
Over the past week, the price has changed by +4.45%, over one month by +13.46%, over three months by +27.14% and over the past year by +39.23%.
Over the past week, the price has changed by +4.45%, over one month by +13.46%, over three months by +27.14% and over the past year by +39.23%.
Is NTR a buy, sell or hold?
Nutrien has received a consensus analysts rating of 3.88.
Therefore, it is recommended to buy NTR.
- StrongBuy: 10
- Buy: 5
- Hold: 8
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the NTR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.9 | -3.1% |
| Analysts Target Price | 68.9 | -3.1% |
| ValueRay Target Price | 84 | 18.1% |
NTR Fundamental Data Overview January 26, 2026
P/E Trailing = 19.1051
P/E Forward = 14.4092
P/S = 1.3448
P/B = 1.364
P/EG = 0.6571
Revenue TTM = 26.56b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 5.61b USD
Long Term Debt = 9.85b USD (from longTermDebt, last quarter)
Short Term Debt = 3.37b USD (from shortTermDebt, last quarter)
Debt = 14.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.56b USD (from netDebt column, last quarter)
Enterprise Value = 48.08b USD (34.52b + Debt 14.18b - CCE 624.0m)
Interest Coverage Ratio = 4.66 (Ebit TTM 3.22b / Interest Expense TTM 691.6m)
EV/FCF = 21.69x (Enterprise Value 48.08b / FCF TTM 2.22b)
FCF Yield = 4.61% (FCF TTM 2.22b / Enterprise Value 48.08b)
FCF Margin = 8.35% (FCF TTM 2.22b / Revenue TTM 26.56b)
Net Margin = 6.79% (Net Income TTM 1.80b / Revenue TTM 26.56b)
Gross Margin = 30.19% ((Revenue TTM 26.56b - Cost of Revenue TTM 18.54b) / Revenue TTM)
Gross Margin QoQ = 32.70% (prev 30.42%)
Tobins Q-Ratio = 0.93 (Enterprise Value 48.08b / Total Assets 51.83b)
Interest Expense / Debt = 1.19% (Interest Expense 168.1m / Debt 14.18b)
Taxrate = 26.37% (166.1m / 629.9m)
NOPAT = 2.37b (EBIT 3.22b * (1 - 26.37%))
Current Ratio = 1.41 (Total Current Assets 14.47b / Total Current Liabilities 10.27b)
Debt / Equity = 0.56 (Debt 14.18b / totalStockholderEquity, last quarter 25.12b)
Debt / EBITDA = 2.42 (Net Debt 13.56b / EBITDA 5.61b)
Debt / FCF = 6.12 (Net Debt 13.56b / FCF TTM 2.22b)
Total Stockholder Equity = 24.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 1.80b / Total Assets 51.83b)
RoE = 7.31% (Net Income TTM 1.80b / Total Stockholder Equity 24.66b)
RoCE = 9.33% (EBIT 3.22b / Capital Employed (Equity 24.66b + L.T.Debt 9.85b))
RoIC = 6.38% (NOPAT 2.37b / Invested Capital 37.15b)
WACC = 5.36% (E(34.52b)/V(48.70b) * Re(7.21%) + D(14.18b)/V(48.70b) * Rd(1.19%) * (1-Tc(0.26)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.92%
[DCF Debug] Terminal Value 81.72% ; FCFF base≈2.26b ; Y1≈1.57b ; Y5≈799.4m
Fair Price DCF = 24.07 (EV 25.19b - Net Debt 13.56b = Equity 11.63b / Shares 483.3m; r=5.90% [WACC]; 5y FCF grow -35.86% → 2.90% )
[DCF Warning] FCF declining rapidly (-35.86%), DCF may be unreliable
EPS Correlation: -61.16 | EPS CAGR: -58.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: -36.84 | Revenue CAGR: -5.23% | SUE: 0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.48 | Chg30d=-0.046 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=4.73 | Chg30d=+0.077 | Revisions Net=+1 | Growth EPS=+2.6% | Growth Revenue=+0.7%
P/E Forward = 14.4092
P/S = 1.3448
P/B = 1.364
P/EG = 0.6571
Revenue TTM = 26.56b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 5.61b USD
Long Term Debt = 9.85b USD (from longTermDebt, last quarter)
Short Term Debt = 3.37b USD (from shortTermDebt, last quarter)
Debt = 14.18b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.56b USD (from netDebt column, last quarter)
Enterprise Value = 48.08b USD (34.52b + Debt 14.18b - CCE 624.0m)
Interest Coverage Ratio = 4.66 (Ebit TTM 3.22b / Interest Expense TTM 691.6m)
EV/FCF = 21.69x (Enterprise Value 48.08b / FCF TTM 2.22b)
FCF Yield = 4.61% (FCF TTM 2.22b / Enterprise Value 48.08b)
FCF Margin = 8.35% (FCF TTM 2.22b / Revenue TTM 26.56b)
Net Margin = 6.79% (Net Income TTM 1.80b / Revenue TTM 26.56b)
Gross Margin = 30.19% ((Revenue TTM 26.56b - Cost of Revenue TTM 18.54b) / Revenue TTM)
Gross Margin QoQ = 32.70% (prev 30.42%)
Tobins Q-Ratio = 0.93 (Enterprise Value 48.08b / Total Assets 51.83b)
Interest Expense / Debt = 1.19% (Interest Expense 168.1m / Debt 14.18b)
Taxrate = 26.37% (166.1m / 629.9m)
NOPAT = 2.37b (EBIT 3.22b * (1 - 26.37%))
Current Ratio = 1.41 (Total Current Assets 14.47b / Total Current Liabilities 10.27b)
Debt / Equity = 0.56 (Debt 14.18b / totalStockholderEquity, last quarter 25.12b)
Debt / EBITDA = 2.42 (Net Debt 13.56b / EBITDA 5.61b)
Debt / FCF = 6.12 (Net Debt 13.56b / FCF TTM 2.22b)
Total Stockholder Equity = 24.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.48% (Net Income 1.80b / Total Assets 51.83b)
RoE = 7.31% (Net Income TTM 1.80b / Total Stockholder Equity 24.66b)
RoCE = 9.33% (EBIT 3.22b / Capital Employed (Equity 24.66b + L.T.Debt 9.85b))
RoIC = 6.38% (NOPAT 2.37b / Invested Capital 37.15b)
WACC = 5.36% (E(34.52b)/V(48.70b) * Re(7.21%) + D(14.18b)/V(48.70b) * Rd(1.19%) * (1-Tc(0.26)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.92%
[DCF Debug] Terminal Value 81.72% ; FCFF base≈2.26b ; Y1≈1.57b ; Y5≈799.4m
Fair Price DCF = 24.07 (EV 25.19b - Net Debt 13.56b = Equity 11.63b / Shares 483.3m; r=5.90% [WACC]; 5y FCF grow -35.86% → 2.90% )
[DCF Warning] FCF declining rapidly (-35.86%), DCF may be unreliable
EPS Correlation: -61.16 | EPS CAGR: -58.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: -36.84 | Revenue CAGR: -5.23% | SUE: 0.84 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.48 | Chg30d=-0.046 | Revisions Net=-2 | Analysts=8
EPS next Year (2026-12-31): EPS=4.73 | Chg30d=+0.077 | Revisions Net=+1 | Growth EPS=+2.6% | Growth Revenue=+0.7%